Only a year after its incorporation, OBaris AG was acquired by Johnson & Johnson, marking the beginning of a new phase of innovation in drug delivery. As a pre-clinical medtech company, OBaris AG was advancing a proprietary technology platform designed to transform the administration of peptide-based therapeutics, offering a painless and patient-friendly alternative to traditional injections..

仅在公司成立一年后，OBaris AG 被强生公司收购，这标志着药物递送创新新阶段的开始。作为一家临床前的医疗技术公司，OBaris AG 正在推进一个专有技术平台，该平台旨在转变基于肽的治疗药物的给药方式，提供一种无痛且对患者友好的传统注射替代方案。

OBaris AG

欧巴里斯股份公司

is a preclinical-stage spin-off from ETH Zurich and the University Hospital Zurich (USZ) founded in 2024. Following six years of research, the startup has developed a technology platform,

是一家源自苏黎世联邦理工学院（ETH Zurich）和苏黎世大学医院（USZ）的临床前阶段分拆公司，成立于2024年。经过六年的研究，这家初创公司开发了一个技术平台，

OctoPatch

八达通补丁

, a painless suction patch that can be easily self-applied to the inner side of a person’s cheek. The patch design is inspired by an octopus sucker: it applies negative pressure to the buccal mucosa, and together with natural permeation enhancers, it temporarily disrupts the barrier, enabling drugs to efficiently reach the bloodstream.

一种无痛的吸力贴片，可以轻松地自行贴在人的脸颊内侧。该贴片的设计灵感来源于章鱼的吸盘：它对颊粘膜施加负压，并结合天然渗透增强剂，暂时破坏屏障，使药物能够高效进入血液。

The patch, spanning a few millimeters in diameter, stays in place for a very short period of time, before it is removed..

这个直径几毫米的贴片在被移除之前，只会在原地停留很短的一段时间。

The technology platform can be used across multiple therapeutic indications. To this end, however, OBaris has conducted a proof-of-concept study with drugs used in treatment of metabolic diseases, such as diabetes, obesity, and osteoporosis, demonstrating the potential of their solution – the results are promising..

该技术平台可跨多种治疗适应症使用。然而，为此，OBaris 已经进行了一项概念验证研究，使用了用于治疗代谢性疾病（如糖尿病、肥胖症和骨质疏松症）的药物，证明了他们解决方案的潜力——结果令人鼓舞。

The startup has now joined the

这家初创公司现在已经加入了

Johnson & Johnson

强生公司

family to further develop OctoPatch and OBaris co-founders,

家族进一步开发OctoPatch和OBaris的联合创始人，

David Klein Cerrejon

大卫·克莱因·塞雷洪

and

和

Nevena Paunović

内韦娜·保诺维奇

will continue as part of the Johnson & Johnson team where they will further advance their platform technology.

将继续作为强生团队的一部分，进一步推进他们的平台技术。

“This acquisition is the result of strong technology development, the dedication of the OBaris team, and the invaluable support we’ve received from a strong network of individuals, as well as from the academic and start-up ecosystem”, comments the co-founders. “With its vast experience in drug development, Johnson & Johnson is an ideal partner to advance the technology and bring it to patients.”.

“这次收购是强大的技术开发、OBaris团队的奉献精神以及我们从强大的个人网络、学术界和初创企业生态系统中获得的宝贵支持的结果，”联合创始人评论道。“凭借其在药物开发方面的丰富经验，强生公司是推进该技术并将其带给患者的理想合作伙伴。”

Prior to the exit, OBaris did not secure equity funding. Instead, the startup was supported by several ecosystem players, who provided over CHF 1 million in investment in the form of non-dilutive funds and convertible loans. Among the supporters are organizations such as the

在退出之前，OBaris 并未获得股权融资。相反，该初创公司得到了多个生态系统参与者的支持，他们以非稀释性资金和可转换贷款的形式提供了超过 100 万瑞士法郎的投资。支持者中包括诸如

ETH Foundation

以太坊基金会

,

，

USZ Foundation

美国瑞士基金会

, Evi-Diethelm Winterle Stiftung,

，Evi-Diethelm Winterle 基金会，

Gebert Rüf Stiftung

格贝尔特·吕夫基金会

,

，

Innosuisse

瑞士创新局

,

，

Swiss National Science Foundation SNSF

瑞士国家科学基金会 SNSF

and

和

Venture Kick

创业启动

as well as

以及

Lenz & Staehelin

兰茨与施泰林

as their legal advisor.

作为他们的法律顾问。

(RAN)

(无线接入网)

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送